Compare Brookfield Asset Management Inc Class A Limited Voting Shares (BAM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Asset Management Inc Class A Limited Voting Shares vs Eli Lilly And Co — how do they compare? Brookfield Asset Management Inc Class A Limited Voting Shares trades at $47.67 (market cap $73.40B), while Eli Lilly And Co trades at $1,305.24 (market cap $1.13T). The key difference: Eli Lilly And Co is far larger — about 15.4× Brookfield Asset Management Inc Class A Limited Voting Shares's market cap, and Brookfield Asset Management Inc Class A Limited Voting Shares pays the higher dividend (4.36%). Which is the better fit depends on your goals — on Pluang, investors hold Brookfield Asset Management Inc Class A Limited Voting Shares for 4 Days and Eli Lilly And Co for 94 Days on average.
| BAM | LLY | |
|---|---|---|
Market Cap | $73.40B | $1.13T |
Volume | 1,966,191 | 1,874,070 |
Sector | Financials | Health |
52-Week High | $55.86 | $1.28K |
52-Week Low | $42.87 | $812.43 |
Typical Hold Time | 4 Days | 94 Days |
Enterprise Value | $77.16B | $1.18T |
Dividend Yield | 4.36% | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Eli Lilly (LLY) trades at $1,306.69, up 1.79% today, with a bullish technical signal and strong fundamentals. The company reported revenue of $65.18B in 2025, with net income surging to $20.64B, and has consistently beaten EPS estimates. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership. Valuation ratios are elevated, with a P/E of 42.66 and P/S of 14.3, reflecting high growth expectations.
Outlook remains positive driven by robust drug pipeline and expanding market share, though high valuation and competitive pressures pose risks. Analyst consensus is strongly bullish with a $1,360 price target, but investors should monitor execution risks and regulatory developments. The stock's proximity to all-time highs suggests momentum but warrants caution for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Asset Management Inc Class A Limited Voting Shares
Brookfield Asset Management manages capital for institutional and individual investors across alternative asset classes, including renewable power, infrastructure, real estate, private equity, and credit. The company operates as a separately listed manager, distinct from parent company Brookfield Corporation.
Read more on BAM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
